Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$4.01 -12.6%	$4.16	$3.35 ▼ $22.00	$118.75M	0.52	87,331 shs	222,765 shs
MNMD Mind Medicine (MindMed)	$6.74 -1.5%	$6.87	$4.70 ▼ $10.44	$516.78M	2.52	1.36 million shs	658,218 shs
PGEN Precigen	$1.43 +0.7%	$1.44	$0.65 ▼ $2.17	$419.16M	1.84	1.38 million shs	1.44 million shs
STOK Stoke Therapeutics	$11.84 +0.3%	$10.14	$5.35 ▼ $16.15	$644.79M	1.09	686,131 shs	552,304 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	-12.64%	+9.86%	+14.25%	-43.28%	-80.72%
MNMD Mind Medicine (MindMed)	-1.46%	-4.94%	-5.60%	+8.89%	-7.29%
PGEN Precigen	+0.70%	-4.03%	+1.42%	-10.06%	-7.74%
STOK Stoke Therapeutics	+0.25%	+2.33%	+28.98%	+64.22%	-8.36%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	2.7285 of 5 stars	3.6	3.0	0.0	1.9	0.8	1.3
MNMD Mind Medicine (MindMed)	1.6209 of 5 stars	3.6	0.0	0.0	2.2	0.8	0.6
PGEN Precigen	4.0183 of 5 stars	3.5	1.0	4.7	2.7	1.7	0.6
STOK Stoke Therapeutics	4.0885 of 5 stars	3.6	0.0	4.8	3.3	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	461.10% Upside
MNMD Mind Medicine (MindMed)	3.27	Buy	$25.50	278.34% Upside
PGEN Precigen	3.00	Buy	$6.00	319.58% Upside
STOK Stoke Therapeutics	3.29	Buy	$23.20	95.95% Upside

Current Analyst Ratings Breakdown

Latest CTNM, PGEN, MNMD, and STOK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/9/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	2.07	N/A	N/A	$7.66 per share	0.52
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$3.21 per share	N/A
PGEN Precigen	$3.92M	107.68	N/A	N/A	$0.13 per share	11.00
STOK Stoke Therapeutics	$36.56M	17.68	N/A	N/A	$4.32 per share	2.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
MNMD Mind Medicine (MindMed)	-$108.68M	-$1.29	N/A	N/A	N/A	N/A	-40.33%	-32.13%	8/12/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	14.99	N/A	N/A	26.33%	19.08%	15.72%	8/5/2025 (Estimated)

Latest CTNM, PGEN, MNMD, and STOK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
MNMD Mind Medicine (MindMed)	0.10	7.27	7.27
PGEN Precigen	N/A	3.53	3.53
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
MNMD Mind Medicine (MindMed)	27.91%
PGEN Precigen	33.51%
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
MNMD Mind Medicine (MindMed)	2.45%
PGEN Precigen	47.10%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
MNMD Mind Medicine (MindMed)	40	75.55 million	73.70 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

CTNM, PGEN, MNMD, and STOK Headlines

Recent News About These Companies

Stoke Therapeutics (NASDAQ:STOK) Trading Down 3.5% - Here's Why

June 26 at 2:41 PM | marketbeat.com

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 17, 2025 | businesswire.com

STOK FY2025 EPS Forecast Lowered by Cantor Fitzgerald

June 16, 2025 | marketbeat.com

Stoke Therapeutics: Impressive Pipeline And Big Backers

June 15, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Sells 391,322 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 15, 2025 | marketbeat.com

Cantor Fitzgerald Predicts STOK FY2026 Earnings

June 10, 2025 | marketbeat.com

Kangaroo Care Awareness Day celebrated at Stoke Mandeville Hospital

June 10, 2025 | msn.com

Jong Oranje and Stoke City star is open to transfer: “Of course, I have my ambitions”

June 10, 2025 | sports.yahoo.com

Stoke City confirm next stage of major badge consultation

June 10, 2025 | msn.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 10, 2025 | marketbeat.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Two Sigma Investments LP

June 9, 2025 | marketbeat.com

Jane Street Group LLC Sells 318,465 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 8, 2025 | marketbeat.com

Stoke City Secure Youth International Amid Leeds United Interest

June 7, 2025 | therealefl.co.ukT

Five hours of 'thundery showers' to rock Stoke-on-Trent today

June 7, 2025 | msn.com

Business forum will look at how the Stoke-on-Trent and Staffordshire area sells itself to the world

June 7, 2025 | expressandstar.comE

Celebrations as Stoke-on-Trent turns 100 years old

June 7, 2025 | bbc.comB

Leeds United dealt transfer blow as Stoke City near 'two-year deal' for England youth international

June 7, 2025 | yorkshirepost.co.ukY

Huddersfield Town confirm departure of 125-appearance man as Stoke City snap up former Hull City target

June 7, 2025 | yorkshirepost.co.ukY

Live updates as Lancaster Bomber performing Stoke-on-Trent flypast

June 7, 2025 | stokesentinel.co.ukS

Jon Walters opens up on Sorba Thomas transfer tussle as Stoke City make first move

June 7, 2025 | msn.com

Millennium Management LLC Increases Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)

June 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PGEN, MNMD, and STOK Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$4.01 -0.58 (-12.64%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$4.08 +0.07 (+1.62%)

As of 06/26/2025 07:30 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Mind Medicine (MindMed) NASDAQ:MNMD

$6.74 -0.10 (-1.46%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$6.78 +0.04 (+0.59%)

As of 06/26/2025 07:47 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Precigen NASDAQ:PGEN

$1.43 +0.01 (+0.70%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.43 0.00 (0.00%)

As of 04:37 AM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Stoke Therapeutics NASDAQ:STOK

$11.84 +0.03 (+0.25%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$11.87 +0.03 (+0.25%)

As of 06/26/2025 07:56 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time